Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
3(100.0%)
3Total
Early Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06735508Early Phase 1Not Yet Recruiting

MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer

Role: collaborator

NCT06195124Early Phase 1Recruiting

A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease

Role: collaborator

NCT06156267Early Phase 1Not Yet Recruiting

Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino

Role: collaborator

All 3 trials loaded